Conclusions Whole flaxseed , but not flaxseed oil and lignan extract , has significant effects on improving glycemic control .
Context The results of human clinical trials investigating the effects of flaxseed on glucose control and insulin sensitivity are inconsistent .
Objective The present study aim ed to systematic ally review and analyze r and omized controlled trials assessing the effects of flaxseed consumption on glycemic control .
No evidence of hypoglycemia or hypotension in older adults during 6 months of flax lignan supplementation in a randomized controlled trial: A safety evaluation
Abstract Context : The natural health product , BeneFlax , is a st and ardized flaxseed [ Linum usitatissimum L. ( Linaceae ) ] lignan enriched product with evidence of product quality and known quantity of the bioactive component , lignan . The acceptance of this natural health product for its various health benefits requires greater evidence of its safety in the general population . Objective : We determined whether flaxseed lignan causes clinical hypoglycemia or hypotension in healthy older adults as an important aspect of safety . Material s and methods : Participants aged 49–87 years were r and omized in a double-blind trial to receive flaxseed lignan ( 543 mg/day in BeneFlax ) or placebo while completing a 6-month walking program . The 94 participants who completed the study were stratified by age ( < 65 years versus ≥65 years ) and treatment category to determine whether older adults were more susceptible to adverse effects . Results : After 6 months of treatment , average plasma glucose level ( 5.4 ± 0.6 mmol/L ) , systolic blood pressure ( 127 ± 14 mm Hg ) , and diastolic blood pressure ( 80 ± 9 mm Hg ) were within normal clinical range . Controlling for sex and body mass index covariates result ed in no observed differences between plasma glucose or blood pressure measurements between treatment or age groups ( p > 0.05 ) . No incidents of hypoglycemia or hypotension were observed during BeneFlax treatment , suggesting that 543 mg falls at or below the no observable adverse effect level ( NOAEL ) . Discussion and conclusion : These data suggest the flaxseed lignan product BeneFlax does not pose a risk of hypoglycemia or hypotension in healthy adults aged 49–87 years
Conclusions Whole flaxseed , but not flaxseed oil and lignan extract , has significant effects on improving glycemic control .
Context The results of human clinical trials investigating the effects of flaxseed on glucose control and insulin sensitivity are inconsistent .
Objective The present study aim ed to systematic ally review and analyze r and omized controlled trials assessing the effects of flaxseed consumption on glycemic control .